Analysed NRX PHARMACEUTICALS INC (NRXP:NASDAQ) News Sources
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company’s first Chief Commercial Officer
13-04-2026
yahoo.com
NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx’s Preservative-Free Ketamine Application
06-04-2026
yahoo.com
Hope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered “Depression Thermometer” Across its Interventional Psychiatry Network
30-03-2026
yahoo.com
NRx Pharmaceuticals (NASDAQ:NRXP) Is In A Good Position To Deliver On Growth Plans
29-03-2026
yahoo.com
New to The Street Broadcasts Show #740 on Bloomberg Television at 6:30 PM EST Featuring Medicus (MDCX), Acme Markets- Canton Foundation, Alpha Ton Capital (ATON), and Virtuix Holdings (NASDAQ:VTIX)
28-03-2026
yahoo.com
NRx Pharmaceuticals (NRXP) Looks to Score Double With ANDA and NDA Filings For NRX-101
25-03-2026
yahoo.com
NRX Pharmaceuticals Inc (NRXP) Q4 2025 Earnings Call Highlights: Strategic Advances and ...
24-03-2026
yahoo.com
What is the current price of NRX PHARMACEUTICALS INC (NRXP:NASDAQ)?
The current price of NRX PHARMACEUTICALS INC (NRXP:NASDAQ) is $2.28.
NRX PHARMACEUTICALS INC (NRXP:NASDAQ) absolute price change since previous trading day?
The absolute price change of NRX PHARMACEUTICALS INC (NRXP:NASDAQ) since the previous trading day is $0.06.
NRX PHARMACEUTICALS INC (NRXP:NASDAQ) percentage price change since previous trading day?
The percentage price change of NRX PHARMACEUTICALS INC (NRXP:NASDAQ) since the previous trading day is 2.7027%.
What is the most recent average sentiment score for NRX PHARMACEUTICALS INC (NRXP:NASDAQ)?
The most recent average sentiment score for NRX PHARMACEUTICALS INC (NRXP:NASDAQ) is 76 out of 100.
What is the most recent average sentiment for NRX PHARMACEUTICALS INC (NRXP:NASDAQ)?
The most recent sentiment for NRX PHARMACEUTICALS INC (NRXP:NASDAQ) is .
SEC-8K** Filing Available For NRX PHARMACEUTICALS INC (NRXP:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.